Drug Use Evaluation of Clindamycin in Critical Care Units in Alexandria Main University Hospital
NCT ID: NCT05223400
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
99 participants
OBSERVATIONAL
2022-03-01
2022-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Infusion of Linezolid Versus Intermittent Dosing in the Treatment of Nosocomial Pneumonia
NCT04531332
Efficacy and Safety of Colistin Based Antibiotic Therapy
NCT04764058
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
NCT02439359
Beta-lactams Therapeutic Drug Monitoring in Critically Ill Patients
NCT05352997
Effect of Aerosolised Colistin in Ventilator Associated Pneumonia
NCT02683603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clindamycin Injection
it is a clindamycin use evaluation study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients on clindamycin as an empirical treatment.
* Patients started clindamycin as an emperical treatment in other departments but the physician approved to continue it in critical care.
Exclusion Criteria
* Patients started clindamycin as a defenitive treatment (based on microbiological culture results).
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Heba Shaker
supervisor of clinical pharmacy unit in Alexandria Main University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Mdicine
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0305292
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.